At UBS Conference, Three RNAi Chiefs Talk Drugs, Alliances, Spin-Outs, and Baby Steps | GenomeWeb

The chief executives of three RNAi drug developers — Sirna Therapeutics, CytRx, and Nastech Pharmaceutical — presented this week at the UBS Global Specialty Pharmaceuticals Conference in New York, giving a few new details about their efforts with the gene-silencing technology.

For Sirna, the only pure-play RNAi firm to present at the event, the talk was all RNAi, with pipeline updates and some insights into how the company plans to structure its future corporate collaborations.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.